An interventional study of Taking Charge during Treatment (TCT) Intervention in Breast Cancer, sponsored by Medical College of Wisconsin. Active, not recruiting at 2 sites in United States. Open to female participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-07-14.
Sponsored by Medical College of Wisconsin · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Breast Neoplasms by Medical College of Wisconsin — 7 open to participants now, 11 under way, none of them phase 3. Breast Neoplasms · Medical College of Wisconsin.
Among the 23 studies in Breast Neoplasms by Medical College of Wisconsin, this one is the 6th largest by planned enrollment of the 17 interventional ones that give a count, is one of 2 that started in 2022, is one of 12 with no phase, reaches primary completion later than 2 of the 10 other live ones, and was the 14th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →7 of the 23 studies in Breast Neoplasms by Medical College of Wisconsin are open now, in 1 country. Recruiting first, the newest first:
Medical College of Wisconsin · Sites in United States
Ages 65+
Medical College of Wisconsin · Sites in United States
Ages 18+ · Women only
Medical College of Wisconsin · Sites in United States
Ages 18+
Medical College of Wisconsin · Sites in United States
Ages 30–75 · Healthy volunteers
Medical College of Wisconsin · Sites in United States
Ages 18+ · Women only
By country, each count listing its studies:
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years to 100 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80 is above the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 45 across the 17 interventional studies, 75 across the 6 observational. Of the 10 that completed or were terminated, 2 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
Medical College of Wisconsin is the lead sponsor of 550 studies on the registry; 123 are open to participants now.
Of its 76 completed or terminated interventional studies of FDA-regulated products, 58 (76%) have results posted.
4 of the studies in Breast Neoplasms by Medical College of Wisconsin that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05223322Medical College of WisconsinUnderstanding and Addressing Disparities in Cancer Therapy Induced Inflammation and Associated Endothelial Dysfunction | 2026-12-31 |
| NCT07227077Medical College of WisconsinDosing Physical Activity Among Older Cancer Survivors Who Experience Chronic Pain: a Micro-randomized Trial | 2027-05-01 |
| NCT02783664Medical College of WisconsinEvaluating the Effects of Genetic Testing on Patients' Stress Levels | 2027-07 |
| NCT06106477Medical College of WisconsinImpact of Intermittent Fasting on Biomarkers of Inflammation and Health-Related Quality of Life: A Feasibility Trial for Women With HR+/HER2- Early Breast Cancer | 2027-07-15 |
Add all 4 to your calendar (.ics) → With an account.
Among the 23 studies in Breast Neoplasms by Medical College of Wisconsin, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Very little is understood about the off-target vascular mechanisms of anti-cancer drug toxicity and the impact of exercise on these changes. Much of what has been learned about molecular pathways regulating vascular endothelial function has been established by logical expansion of knowledge obtained through experimental studies (e.g., discovery of endothelium-derived relaxing factor/nitric oxide). Within the last 10 years technological advancements of -omics approaches, such as RNA-sequencing and shotgun proteomics, have dramatically reduced the cost and technical challenge of accessing these tools for discovery-based research. Investigators are now able to obtain unbiased datasets showing changes in transcript or protein expression within complex samples. With cost and accessibility of sequencing is no longer being substantial bottleneck, one of major challenges researchers now face is determining how to meaningfully interpret profiles from large datasets. The extensive characterization of molecular pathways impacting inflammatory responses, endothelial function and angiogenesis, the pathway and network analysis tools will be an asset for identification molecular pathways relevant to alterations in microvascular endothelial function. The investigators preliminary studies on only a small number of samples highlights this potential of the proposed approach to lead to identify personalized medicine-based profiles that will predict patients are likely to develop microvascular endothelial dysfunction from CTx.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Taking Charge during Treatment (TCT) Intervention. TCT is a 16-20week intervention that promotes adoption of the ACSM exercise guidelines for cancer survivors during treatment, including regular moderate to vigorous physical activity (150 minutes per week of moderate activity or 75 minutes per week of vigorous activity) and a minimum of twice weekly resistance training (RT) minutes during CTx and after. Participants will receive "Take Charge" program binder, 2-4 x weekly text messaging, activity tracker and resistance bands.
Behavioral: Taking Charge during Treatment (TCT) Intervention
To ensure scientific rigor allowing us to test causal pathways associated with exercise, women will be randomized to the TCT intervention or control group arm. The control group will not receive the TCT intervention The investigators experience teaches us that to increase the likelihood of retaining control group participants, the investigators must offer some resources. Thus, the investigators will provide the control group with a one-page summary of the American College of Sports Medicine exercise recommendations, and the "Take Charge" program binder at the completion of the study. Participants will also receive resistance bands and activity tracker at the end of the study. 95 The investigators will also send weekly text messages with supportive content not related to exercise or lifestyle (i.e., a riddle, "take a moment to smile today," a picture of a baby animal).
CT is a 16-20week intervention that promotes adoption of the ACSM exercise guidelines for cancer survivors during treatment, including regular moderate to vigorous physical activity (150 minutes per week of moderate activity or 75 minutes per week of vigorous activity) and a minimum of twice weekly resistance training (RT) minutes during CTx and after. Program components include (1) a binder of information, (2) weekly coaching, (3) 2-4x weekly text messaging and (4) exercise supplies. The TCT program is grounded in Social Cognitive Theory.
Maximal Exercise: Maximal oxygen consumption will be evaluated using cycle ergometry or treadmill to exhaustion as described in the Integrative Physiology Laboratory at each testing visit.
Investigators will use a graded protocol, starting at 50 watts followed by 30 watt increments every 2 minutes. Subjects will be connected to a breath-by-breath metabolic system (Cosmed, Italy) for measurement of VO2peak. A maximal effort will be defined as fulfillment of three of the following criteria: 1) A plateau in VO2 with an increase in work rate defined as an increase in VO2 of less than 50 ml/min; 2) A maximal HR within 10 beats of predicted maximal heart rate; 3) A respiratory exchange ratio of greater than 1.15; 4) No increase in heart rate with an increase in work rate (less than 3 beats); or 5) A rating of perceived exertion of 18 or greater on the Borg scale. These criteria are according to and consistent with the AHA exercise testing guidelines and performed regularly in Dr. Phillips' and Dr. Durand's laboratory groups59, 62-66.
Time frame: T1 (baseline), T2 (18-24 weeks), and T3 (12 months)
Functional Assessment of Cancer Therapy - General (FACT-B)
This survey measures physical, social, emotional, and functional wellbeing and wellness and symptoms associated with breast cancer and its treatments.
Time frame: T1 (baseline), T2 (18-24 weeks), and T3 (12 months)
The Distress Thermometer
This is a simple tool to effectively screen for symptoms of distress.
Time frame: T1 (baseline), T2 (18-40 weeks), and T3 (12-15 months)
Perceived Stress Scale
This survey is a class stress assessment to help understand how different situations affect feelings and perceived stress, asking about thoughts and feelings.
Time frame: T1 (baseline), T2 (18-40 weeks), and T3 (12-15 months)
Hospital Anxiety and Depression Scale
This will measure anxiety and depression in a general medical population of patients.
Time frame: T1 (baseline), T2 (18-40 weeks), and T3 (12-15 months)
The Functional Assessment of Chronic Illness Therapy - Fatigue
Participants will self-report fatigue and its impact upon daily activities and function.
Time frame: T1 (baseline), T2 (18-40 weeks), and T3 (12-15 months)
PROMIS - Social Support
This survey will assess how much social support each individual has in their personal network.
Time frame: T1 (baseline), T2 (18-40 weeks), and T3 (12 months)
PROMIS - Pain Interference
This instrument will measure the self-reported consequences of pain on relevant aspects of a person's life.
Time frame: T1 (baseline), T2 (18-24 weeks), and T3 (12-15 months)
Assess mitochondrial DNA damage
Mitochondrial DNA damage will be assessed in isolated vessels from biopsies and total peripheral blood mononuclear blood cells (PBMCs) via a well-established PCR protocol. Similarly, a PCR based method is used to quantify levels of cell free mtDNA in plasma samples from study participants.
Time frame: T1 (baseline), T2 (18-40 weeks), and T3 (12-15 months)
Cytokine analysis
Investigators will utilize Isoplex platform via CodePlex Human Cytokine Storm Panel-8 to quantify a large array of inflammatory cytokines using minimal amounts (\<30 ul) of plasma sample.
Time frame: T1 (baseline), T2 (18-40 weeks), and T3 (12-15 months)
Gene Express Profiling
Transcriptomic expression profiling of PBMC and endothelial cells will be performed utilizing existing infrastructure (Genomic Sciences and Precision Medicine Center at MCW). RNA sequencing will be performed Illumina on NovaSeq sequencer.
Time frame: T1 (baseline), T2 (18-40 weeks), and T3 (115 months)
Endothelial function
Microvascular function from gluteal and surgical fat biopsies will be used to test the direct effect of clinically used chemotherapy on peripheral microvascular function (as surrogate for coronary microvessels). Investigators propose to perform studies before, after the chemotherapy regimen, and at 12 months follow up. Study team evaluate microvascular dilator capacity, both endothelial and smooth muscle mediated, and quantify levels of vasodilators (NO and H2O2) via fluorescent probes.
Time frame: T1 (baseline), T2 (18-40 weeks), and T3 (12-15 months)
Flow Mediated Dilation
Flow mediated dilation of the brachial artery (large conduit vessels) will be assessed using ultrasound in a noninvasive manner.
Time frame: T1 (baseline), T2 (18-40 weeks), and T3 (12 months)
Cardiac function - Echocardiagram
Echocardiograms: Aortic diameter, cardiac output, stroke volume, heart rate, end diastolic, and end systolic volume will be assessed at rest using two-dimensional echocardiography. With subjects in the left lateral position, measurements will be obtained using the two (Parasternal and Short Axis) and four-chamber view.
Time frame: T1 (baseline), T2 (18-40 weeks), and T3 (12-15 months)
Cardiac function - Pulse Wave Velocity
Pulse Wave Velocity: A non-invasive technique will be used to measure arterial stiffness (pulse wave velocity and central pressures). Briefly, investigators will record waveforms at the carotid and femoral arteries using tonometry and a partially inflated pressure cuff placed over the upper arm and thigh. The distance between sites will be determined using a tape measure.
Time frame: T1 (baseline), T2 (18-40 weeks), and T3 (12-15 months)
Cognitive Function
PROMIS - Cognitive Function Short Form: This is a short six-item sub-set scale of the full PROMIS Cognitive Function item bank that assesses patient-perceived cognitive deficits
Time frame: T1 (baseline), T2 (18-40 weeks), and T3 (12-15 months)
DEXA Scan
Body composition: DXA imaging is a 10 minute, noninvasive, technique that provides precise whole-body measurements of fat (total and visceral) and lean mass. Certified DXA technologists will perform and analyze whole body measures using the same machine for each participant at each time point. To ensure reliability and precision, machines are calibrated daily.
Time frame: T1 (baseline), T2 (18-40 weeks), and T3 (12-15 months)
Height and Weight
Height and Weight: To calculate BMI, investigators will will assess height (baseline only) using a portable stadiometer and weight using a digital scale with participants wearing light clothes and no shoes. A 0.2 kg discrepancy in weight or a 0.5 cm discrepancy in height in the first two measurements, will result in a third measurement.
Time frame: T1 (baseline), T2 (18-24 weeks), and T3 (12-15 months)
Accelerometry
Accelerometry. Summary measures of PA levels will be derived from 7-day accelerometer wear data (% time sedentary, % time moderate to vigorous PA, counts per minute). Study team will adopt the common guideline of 10 hours or more of wear time necessary to define a valid day. Investigators will use the Troiano cut points (sedentary, light, moderate, vigorous).
Time frame: T1 (baseline), T2 (18-40 weeks), and T3 (12-15 months)
Physical Activity self report
Godin Leisure Activity Index collects data on mild, moderate, and vigorous activity.
Time frame: T1 (baseline), T2 (18-40 weeks), and T3 (12-15 months)
Pittsburgh Sleep Quality Index
This is an effective instrument used to measure the quality and patterns of sleep in adults. It differentiates "poor" from "good" sleep quality by measuring seven areas.
Time frame: T1 (baseline), T2 (18-40 weeks), and T3 (12-15 months)
Sitting Time Questionnaire
The STQ is a 5-question self-report survey asking about amount of time spent sedentary.
Time frame: T1 (baseline), T2 (18-40 weeks), and T3 (12-15 months)
Handgrip strength
Measured with a Takei handgrip dynamometer. This test of LM function correlates with total body muscle strength73 and mortality74.
Time frame: T1 (baseline), T2 (18-40 weeks), and T3 (12-15 months)
Sit to Stand
Number of completed Sit to Stand repetitions performed in 30 secs using a chair with no arms with a height of approximately 43 cm75.
Time frame: T1 (baseline), T2 (18-40 weeks), and T3 (12-15 months)
6 Minute Walk Test
Total distance traveled in 6 mins is recorded and used to determine endurance.
Time frame: T1 (baseline), T2 (18-40 weeks), and T3 (12-15 months)
Plan to share: Undecided
No publications or documents are linked to this record.
Started Mar 2022 (actual). Primary completion is estimated for Dec 2026, 57 months after the start.
Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 57 months is above that.
Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Medical College of Wisconsin →